'Inside out' signaling promotes tumor growth

‘Inside out’ signaling promotes tumor growth
Pharmacological inhibitor of MLCK MW01-022AZ suppressed tumor inflammation and growth. a Schematic of LLC lung tumor implantation in C57Bl6 mice and MW01-022AZ treatment. b–d Effect of MW01-022AZ on LLC b gross tumor morphology (n = tumors from 6 mice) c tumor volume (n = 9 mice and d tumor weight at endpoint (21 days) (n = 9 mice). *p < 0.0001 for vehicle vs MW01-022AZ treatment, determined by t-test. e FACS profiles and f quantification of Gr1-CD11b+ (p = 0.1146) Gr1loCD11b+ (*p = 0.0402), Gr1hiCD11b+ (*p = 0.0146) myeloid cells in representative MW01-022AZ vs vehicle-treated tumors at endpoint (21 days) (n = 3 mice), determined by t-test. For Facs gating scheme, see Supplementary Fig. 7b. g Quantification and h representative histographs of F4/80+ macrophages (n = sections from 6 mice) *p < 0.0001 for vehicle or MW01-022AZ by t-test, CD31+ blood vessels (n = sections from 7 mice) *p < 0.0001 for vehicle or MW01-022AZ by t-test, CD8+ T cells (n = sections from 9 mice) *p = 0.0244 for vehicle vs MW01-022AZ by Mann–Whitney test in tissues from mice treated with vehicle or MW01-022AZ. i Model of integrin activation demonstrating that cytokine stimulation activates a pathway whereby PI3Kγ induces MLCK210 and myosin activation and colocalization with Rap1, resulting in Rap1-mediated integrin α4 conformation changes and interaction of the integrin with the actin cytoskeleton. Data are presented as mean values ± SEM. Statistical significance determined by Student’s t-test. Experiments were performed twice. Credit: Nature Communications (2022). DOI: 10.1038/s41467-022-29471-6

A specific immune system kinase has been found to promote tumor inflammation and progression, according to a study published in Nature Communications.

Inhibiting the kinase, called PI3K Gamma, suppressed downstream pro-cancer proteins including MLCK210, pointing to possible therapeutic application of these findings.

"The impact of the work is the demonstration that MLCK210 is a druggable target with potential utility in tumor biology," said Daniel Watterson, Ph.D., the John G. Searle Professor of Molecular Biology and Biochemistry, professor of Pharmacology and a co-author of the study.

Inflammation contributes to a wide variety of diseases, including cardiovascular conditions, and cancer. Vascular endothelial cells and cells—monocytes, macrophages and neutrophils—play critical roles in the inflammatory response.

Myeloid cells often migrate to inflamed tissue, but sustained recruitment of these cells can cause induced by release of oxygen radicals, which can also contribute to development of cancer. Such inflamed tissue often occurs in cancer, so controlling myeloid cell recruitment is one possible therapeutic strategy, according to the authors.

In the study, investigators stimulated myeloid cells with a cellular medium containing factors secreted by Lewis Lung carcinoma tumor cells. This medium fools myeloid cells into thinking they are in a cancerous environment, triggering behavior that closely mimics what is seen when they are recruited to the cancer sites.

The scientists discovered that in the cancer microenvironment, the kinase PI3K Gamma activates the MLCK210 protein, which facilitates recruitment of to sites of inflammation. Factors downstream of MLCK210 also improve myeloid cell adhesion to the lining of blood vessels and stimulate tumor progression.

Importantly, much of MLCK210 signaling is accomplished through integrins, which are transmembrane receptors that can mediate from within the cell, according to Watterson.

"The broader impact of this paper is the involvement of an 'inside out' physiological process involving MLCK210, a druggable protein kinase target," Watterson said.

Investigators also tested reducing expression of MLCK210 in mice, finding these MLCK210-negative mice—which were developed by Watterson—had drastically reduced inflammation and tumor growth. Inhibiting the MLCK210 pathway could reduce harmful inflammation and subsequent tumor progression in cancer. These findings are being used in current development of kinase inhibitors for potential drug development, Watterson said.

Complementing the results using the MLCK21-negative , treatment with a small molecule inhibitor of MLCK kinase activity developed in the Watterson laboratory also reduced growth and inflammation.

"The small molecule gets inside the cell and inhibits the MLCK210 activity, not the levels of the MLCK210 protein as in the genetic knockout mouse," Watterson said. "These independent yet complementary approaches are important to demonstrate biological rigor with this pathway."

Explore further

How tumors make immune cells 'go bad'

More information: Michael C. Schmid et al, PI3Kγ stimulates a high molecular weight form of myosin light chain kinase to promote myeloid cell adhesion and tumor inflammation, Nature Communications (2022). DOI: 10.1038/s41467-022-29471-6
Journal information: Nature Communications

Citation: 'Inside out' signaling promotes tumor growth (2022, August 8) retrieved 25 September 2022 from https://medicalxpress.com/news/2022-08-tumor-growth.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors